BioMarin Pharmaceutical Inc
BMRNHealthcare|Biotechnology|USA
$56.02
-0.20 (-0.35%)
DCF (FCF)
$37.55
Tangible Book
$29.52
Graham Number
$45.74
Earnings Power
$19.68
Analyst Ratings
| Firm / Analyst | Rating | Price Target | Date |
|---|---|---|---|
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — |
Analyst Estimates
annual
{
"date": [
"202612",
"202712",
"202812"
],
"revenue_estimate": [
3631.93,
4076.05,
4448.31
],
"ebit_estimate": [
1096.69,
1351.59,
1611.48
],
"ebitda_estimate": [
933.52,
1279.5,
1521.48
],
"net_income_estimate": [
847.36,
1134.98,
1376.93
],
"per_share_eps_estimate": [
4.11,
5.5,
6.87
],
"eps_nri_estimate": [
4.29,
5.66,
7.05
],
"dividend_estimate": [
null,
null,
null
],
"book_value_per_share_estimate": [
39.19,
46.2,
null
],
"pretax_income_estimate": [
1095.22,
1386.35,
1722.24
],
"operating_cash_flow_per_share_estimate": [
5.93,
6.44,
null
],
"roa_estimate": [
10.45,
10.75,
8.5
],
"roe_estimate": [
14.6,
14.15,
12.6
],
"gross_margin_estimate": [
81.63,
82.15,
82.83
],
"operating_cash_flow_estimate": [
1179.46,
1279.9,
null
],
"pettm_estimate": [
13.64,
10.19,
8.16
],
"long_term_growth_rate_mean": 30.89,
"long_term_revenue_growth_rate_mean": "11.45",
"future_per_share_eps_estimate_growth": 53.85,
"future_eps_nri_estimate_growth": 30.89,
"future_revenue_estimate_growth": 11.45,
"future_ebit_estimate_growth": 45.64,
"future_ebitda_estimate_growth": 38.34,
"future_dividend_estimate_growth": null,
"future_net_income_estimate_growth": 55.44,
"future_pretax_income_estimate_growth": 49.98,
"future_book_value_per_share_estimate_growth": null,
"future_roa_estimate_growth": null,
"future_roe_estimate_growth": 24.91,
"future_gross_margin_estimate_growth": 1.99,
"future_operating_cash_flow_per_share_estimate_growth": null
}
quarterly
{
"date": [
"202603",
"202606",
"202609",
"202612",
"202703",
"202706",
"202709",
"202712"
],
"revenue_estimate": [
757.26,
845.79,
959.27,
1045.27,
959.46,
1021.04,
1047.54,
1135.45
],
"ebit_estimate": [
202.9,
253.66,
297.32,
349.2,
322.15,
354.48,
325.97,
385.49
],
"ebitda_estimate": [
212.41,
262.52,
255.64,
290,
null,
null,
null,
null
],
"net_income_estimate": [
153.35,
183.59,
234.39,
285.38,
219.22,
250.95,
221.48,
274.43
],
"per_share_eps_estimate": [
0.77,
0.9,
1.13,
1.37,
1.1,
1.26,
1.1,
1.36
],
"eps_nri_estimate": [
0.76,
0.92,
1.15,
1.41,
1.1,
1.26,
1.1,
1.36
],
"dividend_estimate": [
null,
null,
null,
null,
null,
null,
null,
null
],
"book_value_per_share_estimate": [
null,
null,
null,
null,
null,
null,
null,
null
],
"pretax_income_estimate": [
207.65,
238.83,
301.08,
355.55,
304.57,
344.69,
308.38,
375.7
],
"operating_cash_flow_per_share_estimate": [
null,
null,
null,
null,
null,
null,
null,
null
],
"roa_estimate": [
null,
null,
null,
null,
null,
null,
null,
null
],
"roe_estimate": [
null,
null,
null,
null,
null,
null,
null,
null
],
"gross_margin_estimate": [
81.47,
81.6,
81.3,
81.67,
82,
82,
82,
82
],
"operating_cash_flow_estimate": [
null,
null,
null,
null,
null,
null,
null,
null
],
"pettm_estimate": [
13.41,
12.44,
11.53,
11.59,
11.62,
null,
null,
null
],
"long_term_growth_rate_mean": 30.89,
"long_term_revenue_growth_rate_mean": "11.45",
"future_per_share_eps_estimate_growth": 53.85,
"future_eps_nri_estimate_growth": 30.89,
"future_revenue_estimate_growth": 11.45,
"future_ebit_estimate_growth": 45.64,
"future_ebitda_estimate_growth": 38.34,
"future_dividend_estimate_growth": null,
"future_net_income_estimate_growth": 55.44,
"future_pretax_income_estimate_growth": 49.98,
"future_book_value_per_share_estimate_growth": null,
"future_roa_estimate_growth": null,
"future_roe_estimate_growth": 24.91,
"future_gross_margin_estimate_growth": 1.99,
"future_operating_cash_flow_per_share_estimate_growth": null
}